GLDG vs MGNX Comparison

GoldMining Inc is a mineral exploration company with a focus on the acquisition, exploration, and development of projects in Colombia, Brazil, the United States, Canada, and Peru. Its principal projects are the La Mina Gold project and its Titiribi Gold-Copper project, located in Colombia; the Sao Jorge Gold Project, located in Brazil; and its interest in the Whistler Gold-Copper Project, located in Alaska, United States. Additionally, the company has several other projects in its portfolio, such as the Yellowknife Gold Project, Cachoeira Gold Project, Surubim Gold Project, Yarumalito Gold Project, Rea Uranium Project, etc. The firm has two operating segments, with U.S. GoldMining as one distinct operating segment and all other subsidiaries, or Others, being the second operating segment.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.